1.
Acta Pharmaceutica Sinica B
; (6): 886-902, 2021.
Article
in English
| WPRIM
| ID: wpr-881175
ABSTRACT
Current advances of immunotherapy have greatly changed the way of cancer treatment. At the same time, a great number of nanoparticle-based cancer immunotherapies (NBCIs) have also been explored to elicit potent immune responses against tumors. However, few NBCIs are nearly in the clinical trial which is mainly ascribed to a lack understanding of